Q Denost, M Solomon, J-J Tuech, L Ghouti, E Cotte, Y Panis, B Lelong, P Rouanet, J-L Faucheron, M Jafari, J H Lefevre, E Rullier, A Heriot, K Austin, P Lee, W Brown, H Maillou-Martinaud, H Savel, B Quintard, G Broc, F Saillour-Glénisson
BACKGROUND: Tumour extension beyond the mesorectal plane (ymrT4) occurs in 5-10 per cent of patients with rectal cancer and 10 per cent of patients develop locally recurrent rectal cancer (LRRC) after primary surgery. There is global variation in healthcare delivery for these conditions. METHODS: An international benchmark trial of the management of ymrT4 tumours and LRRC was undertaken in France and Australia between 2015 and 2017. Heterogeneity in management and operative decision-making were analysed by comparison of surgical resection rates, blinded intercountry reading of pelvic MRI, quality-of-life assessment and qualitative evaluations...
December 2020: British Journal of Surgery